BioCryst posts FY 2025 non-GAAP operating profit of USD 214.2 million (+198%)

Reuters02-26
BioCryst posts FY 2025 non-GAAP operating profit of USD 214.2 million (+198%)

BioCryst reported FY 2025 total revenue of USD 874.8 million and ORLADEYO revenue of USD 601.8 million (+38.0% y-o-y). The company posted FY 2025 operating profit of USD 341.0 million and net income of USD 263.9 million, with diluted EPS of USD 1.21. Cash, cash equivalents, restricted cash and investments were USD 337.5 million at Dec. 31, 2025. During 2025, BioCryst completed the sale of its European ORLADEYO business to Neopharmed Gentili, and recorded USD 244.0 million of license revenue in FY 2025 related to the license of intellectual property. The company also received FDA approval for ORLADEYO oral pellets for hereditary angioedema patients aged 2 to <12 years, and completed its acquisition of Astria Therapeutics in January 2026, adding navenibart (Phase 3) to its HAE portfolio. BioCryst maintained FY 2026 global net ORLADEYO revenue guidance of USD 625 million to USD 645 million and total revenue guidance of USD 635 million to USD 660 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260700PRIMZONEFULLFEED9661826) on February 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment